HYTN Innovations Advances Active Pharmaceutical Ingredient Portfolio and Increases Sales of Rapid Onset Cannabis Products Using Proprietary Elevation Technology
VANCOUVER, British Columbia, Feb. 16, 2023 (GLOBE NEWSWIRE) — HYTN Innovations Inc. (“HYTN” or the “Company”) (CSE: HYTN), a leading manufacturer of products containing psychoactive and psychotropic compounds, including cannabis-derived cannabinoids, is pleased to provide an update on its Active Pharmaceutical Ingredient (API) portfolio. The Company’s Kelowna, B.C. facility holds all available licenses and amendments under both the Cannabis Act and the Controlled Drugs and Substances Act, enabling it to be at the forefront of regulatory compliance. As noted in previous news releases these licenses include the following: Dealers Licence, Standard Processing, Standard Cultivation, Medical Sales (with possession), Amendment for Sale to Provincial and Territorial Authorized Retailers and a Research Licence.
Related news for (HYTNF)
- HYTN Completes Acquisition of Prism Scientific Labs, Enhancing Psychedelic Compound Manufacturing Capabilities
- HYTN Awarded Drug Establishment License from Health Canada, Expanding GMP Capabilities
- HYTN Welcomes U.S. Recommendation to Reclassify Cannabis, Foresees Growth
- HYTN Innovates GMP Stability Programs, Sets Industry Benchmark
- HYTN Welcomes Health Canada for Audit to Enhance GMP Capabilities